Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report.
- 22 January 2013
- journal article
- case report
- Vol. 11 (2) , 311-4
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Rituximab therapy for autoimmune haematological diseasesEuropean Journal of Internal Medicine, 2011
- Faculty Opinions recommendation of Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.2006
- Cold agglutinin disease.2006
- Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood, 2005
- Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patientsBlood, 2004
- Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin’s lymphomaAnnals of Oncology, 2001
- Cold agglutinin hemolysis responding to fludarabine therapyAmerican Journal of Hematology, 1996
- Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre.BMJ, 1981
- ‘Incomplete’ Cold Antibodies: Role of Complement in Sensitization to Antiglobulin Serum by Potentially Haemolytic AntibodiesBritish Journal of Haematology, 1957